Amicus Therapeutics FOLD vs. Rigel Pharmaceuticals RIGL: Which Rare Disease Biotech Stock Has Better Upside?

Amicus Therapeutics (FOLD) and Rigel Pharmaceuticals (RIGL) are rare disease biotech stocks with strong growth potential. FOLD's lead product, Galafold, is approved for Fabry disease, while RIGL's Tavalisse targets chronic immune thrombocytopenia. FOLD's potential takeover by BioMarin Pharmaceutical adds upside, while RIGL's growth is tied to execution and pipeline development. FOLD's reliance on Galafold is a concern, but its IP portfolio and strong sales growth make it an attractive option. RIGL's commercial portfolio and pipeline development will drive its growth.